The Latest Headlines at American Banking and Market News
Revolution Medicines, Inc. Forecasted to Post Q2 2024 Earnings of ($0.76) Per Share (NASDAQ:RVMD)
Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) – Investment analysts at Wedbush reduced their Q2 2024 EPS estimates for shares of Revolution Medicines in a research report issued to clients and investors on ... More of this article »
Q2 2024 EPS Estimates for Sonic Automotive, Inc. (NYSE:SAH) Decreased by Analyst
Sonic Automotive, Inc. (NYSE:SAH – Free Report) – Equities researchers at Seaport Res Ptn reduced their Q2 2024 earnings per share estimates for shares of Sonic Automotive in a note issued to investors on Thursday,... More of this article »
Q2 2024 EPS Estimates for Stepan (NYSE:SCL) Decreased by Analyst
Stepan (NYSE:SCL – Free Report) – Equities researchers at Seaport Res Ptn dropped their Q2 2024 earnings estimates for Stepan in a research report issued to clients and investors on Thursday, May 9th. Seaport Res Ptn... More of this article »
Brokers Issue Forecasts for Revolution Medicines, Inc.’s Q2 2024 Earnings (NASDAQ:RVMD)
Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) – Leerink Partnrs upped their Q2 2024 EPS estimates for Revolution Medicines in a research report issued on Wednesday, May 8th. Leerink Partnrs analyst J. Chang... More of this article »
Revolve Group, Inc. to Post Q2 2024 Earnings of $0.12 Per Share, Wedbush Forecasts (NYSE:RVLV)
Revolve Group, Inc. (NYSE:RVLV – Free Report) – Equities research analysts at Wedbush lowered their Q2 2024 earnings per share estimates for Revolve Group in a report released on Wednesday, May 8th. Wedbush analyst... More of this article »
Q2 2024 EPS Estimates for Red Violet, Inc. (NASDAQ:RDVT) Boosted by Analyst
Red Violet, Inc. (NASDAQ:RDVT – Free Report) – Research analysts at B. Riley raised their Q2 2024 earnings per share (EPS) estimates for shares of Red Violet in a report issued on Thursday, May 9th. B. Riley analyst... More of this article »
William Blair Comments on Redfin Co.’s Q2 2024 Earnings (NASDAQ:RDFN)
Redfin Co. (NASDAQ:RDFN – Free Report) – Analysts at William Blair upped their Q2 2024 earnings estimates for shares of Redfin in a research note issued to investors on Wednesday, May 8th. William Blair analyst S. Sheldon... More of this article »
Brokers Set Expectations for Redfin Co.’s Q2 2024 Earnings (NASDAQ:RDFN)
Redfin Co. (NASDAQ:RDFN – Free Report) – Equities researchers at Wedbush cut their Q2 2024 earnings per share (EPS) estimates for shares of Redfin in a report issued on Wednesday, May 8th. Wedbush analyst J. Mccanless... More of this article »
Q2 2024 EPS Estimates for Six Flags Entertainment Co. Cut by B. Riley (NYSE:SIX)
Six Flags Entertainment Co. (NYSE:SIX – Free Report) – Analysts at B. Riley cut their Q2 2024 earnings per share estimates for shares of Six Flags Entertainment in a note issued to investors on Thursday, May 9th. B.... More of this article »
REGENXBIO Inc. to Post Q2 2024 Earnings of ($1.19) Per Share, Leerink Partnrs Forecasts (NASDAQ:RGNX)
REGENXBIO Inc. (NASDAQ:RGNX – Free Report) – Analysts at Leerink Partnrs lowered their Q2 2024 EPS estimates for REGENXBIO in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst M. Foroohar now... More of this article »
RumbleOn, Inc. (NASDAQ:RMBL) to Post Q2 2024 Earnings of ($0.05) Per Share, Wedbush Forecasts
RumbleOn, Inc. (NASDAQ:RMBL – Free Report) – Stock analysts at Wedbush decreased their Q2 2024 EPS estimates for shares of RumbleOn in a research report issued to clients and investors on Thursday, May 9th. Wedbush... More of this article »
Q2 2024 EPS Estimates for Rithm Capital Corp. Cut by Wedbush (NYSE:RITM)
Rithm Capital Corp. (NYSE:RITM – Free Report) – Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for shares of Rithm Capital in a research note issued on Thursday, May 9th. Wedbush analyst... More of this article »
Q2 2024 EPS Estimates for Cartesian Therapeutics, Inc. Boosted by Analyst (NASDAQ:RNAC)
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Investment analysts at Leerink Partnrs upped their Q2 2024 EPS estimates for Cartesian Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink... More of this article »